Biomarker-based therapy in pancreatic ductal adenocarcinoma: An emerging reality? Journal Article

Authors: Krantz, B. A.; O'Reilly, E. M.
Article Title: Biomarker-based therapy in pancreatic ductal adenocarcinoma: An emerging reality?
Abstract: Over the last decade, many of the major solid organ cancers have seen improvements in survival due to development of novel therapeutics and corresponding biomarkers that predict treatment efficacy or resistance. In contrast, favorable outcomes remain challenging in pancreatic ductal adenocarcinoma (PDAC), in part related to the lack of validated biomarkers for patient and treatment selection and thus optimal clinical decision-making. Increasingly, however, therapeutic development for PDAC is accompanied by bioassays to evaluate response and to study mechanism of actions with a corresponding increase in the number of trials in mid to late stage with integrated biomarkers. In addition, blood-based biomarkers that provide a measure of disease activity and allow for minimally invasive tumor analyses are emerging, including circulating tumor DNA, exosomes, and circulating tumor cells. In this article, we review potential biomarkers for currently approved therapies as well as emerging biomarkers for therapeutics under development. © 2017 American Association for Cancer Research.
Keywords: cancer survival; sorafenib; erlotinib; placebo; drug efficacy; patient selection; gemcitabine; colorectal cancer; gastrointestinal stromal tumor; imatinib; stem cell factor receptor; unindexed drug; ca 19-9 antigen; carcinoembryonic antigen; epidermal growth factor receptor; epidermal growth factor receptor 2; lung cancer; cetuximab; tumor marker; cancer therapy; prediction; cancer resistance; panitumumab; drug mechanism; bioassay; pancreas adenocarcinoma; stomach cancer; clinical decision making; estrogen receptor; progesterone receptor; trastuzumab; k ras protein; b raf kinase; circulating tumor cell; disease activity; ribonucleotide reductase; minimally invasive procedure; exosome; dalotuzumab; crizotinib; dabrafenib; trametinib; afatinib; mk 0752; rucaparib; human; priority journal; article; circulating tumor dna; ceritinib; gemcitabine elaidate; solid malignant neoplasm; co 1 01
Journal Title: Clinical Cancer Research
Volume: 24
Issue: 10
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2018-05-01
Start Page: 2241
End Page: 2250
Language: English
DOI: 10.1158/1078-0432.ccr-16-3169
PROVIDER: scopus
PMCID: PMC5955785
PUBMED: 29269376
Notes: Article -- Export Date: 2 July 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Eileen O'Reilly
    316 O'Reilly
  2. Benjamin Krantz
    2 Krantz